等待开盘 05-11 09:30:00 美东时间
+0.150
+2.61%
Truist Securities analyst Srikripa Devarakonda maintains Absci (NASDAQ:ABSI) with a Buy and raises the price target from $9 to $11.
05-08 23:54
Absci shares are trading lower after the company reported mixed Q1 financial re...
05-08 19:58
Absci Corporation reported first quarter 2026 financial results, highlighting progress in its ABS-201 clinical trials for androgenetic alopecia and endometriosis, with favorable safety data and initiation of multiple ascending dose cohorts. The company also expanded its pipeline with ABS-202 for an undisclosed inflammation and immunology indication. Financially, revenue decreased to $0.2 million, R&D expenses rose to $19.3 million, and net loss w...
05-07 20:05
Absci grants 276,200-share inducement stock option at $4.92 exercise price Absci granted non-statutory stock options covering 276,200 common shares to one newly hired non-executive employee on May 1, 2026. Exercise price set at USD 4.92 per share, matching May 1 Nasdaq closing price. Options carry a
05-05 08:15
Absci grants 276,200-share stock option at $4.92 under inducement plan Absci granted a non-statutory stock option for 276,200 common shares to one newly hired non-executive employee on May 1, 2026. Exercise price set at USD 4.92 per share; option term 10 years. Vesting set over four years, with 25%
05-05 08:11
转型锂资源运输!海纳天成国际飙升近240%;X-Energy上市次日续涨超23%,获亚马逊、ARK等明星机构支持>>
04-28 15:42
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Absci业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 2025年第四季度营收为70万美元,主要来源于合作项目的进展。 **费用支出:** - 研发费用为2,530万美元,主要用于内部项目推进,特别是ABS-101和ABS-201的临床前及临床开发 - 销售、一般及行政费用为860万美元 **现金状况:** 截至2025年12月31日,现金、现金等价物及有价证券总额为1.443亿美元 **其他收益:** 公司通过或有对价结算获得510万美元收益,产生870万美元无限制现金 ## 2. 财务指标变化 **营收变化
03-26 12:30
Blaize Holdings, Inc.涨53.15%;中阳金融集团涨36.70%;Next Technology涨35.00%
03-25 15:04